CN100503589C - 作为天冬氨酰蛋白酶抑制剂前药的磺胺衍生物 - Google Patents

作为天冬氨酰蛋白酶抑制剂前药的磺胺衍生物 Download PDF

Info

Publication number
CN100503589C
CN100503589C CNB988132338A CN98813233A CN100503589C CN 100503589 C CN100503589 C CN 100503589C CN B988132338 A CNB988132338 A CN B988132338A CN 98813233 A CN98813233 A CN 98813233A CN 100503589 C CN100503589 C CN 100503589C
Authority
CN
China
Prior art keywords
compound
acid
prodrugs
aspartyl protease
nmr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB988132338A
Other languages
English (en)
Chinese (zh)
Other versions
CN1284071A (zh
Inventor
R·D·唐
M·R·黑尔
C·T·贝克
E·S·福尔芬
I·卡尔多
W·W·卡兹米尔斯基
A·斯帕尔顿斯坦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25544691&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN100503589(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of CN1284071A publication Critical patent/CN1284071A/zh
Application granted granted Critical
Publication of CN100503589C publication Critical patent/CN100503589C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/18—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • C07F9/65842—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring
    • C07F9/65844—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring the phosphorus atom being part of a five-membered ring which may be condensed with another ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
CNB988132338A 1997-12-24 1998-03-09 作为天冬氨酰蛋白酶抑制剂前药的磺胺衍生物 Expired - Lifetime CN100503589C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/998,050 1997-12-24
US08/998,050 US6436989B1 (en) 1997-12-24 1997-12-24 Prodrugs of aspartyl protease inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNA2009101453192A Division CN101565412A (zh) 1997-12-24 1998-03-09 作为天冬氨酰蛋白酶抑制剂前药的磺胺衍生物

Publications (2)

Publication Number Publication Date
CN1284071A CN1284071A (zh) 2001-02-14
CN100503589C true CN100503589C (zh) 2009-06-24

Family

ID=25544691

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA2009101453192A Pending CN101565412A (zh) 1997-12-24 1998-03-09 作为天冬氨酰蛋白酶抑制剂前药的磺胺衍生物
CNB988132338A Expired - Lifetime CN100503589C (zh) 1997-12-24 1998-03-09 作为天冬氨酰蛋白酶抑制剂前药的磺胺衍生物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CNA2009101453192A Pending CN101565412A (zh) 1997-12-24 1998-03-09 作为天冬氨酰蛋白酶抑制剂前药的磺胺衍生物

Country Status (43)

Country Link
US (5) US6436989B1 (US06559137-20030506-C00128.png)
EP (2) EP1944300A3 (US06559137-20030506-C00128.png)
JP (3) JP3736964B2 (US06559137-20030506-C00128.png)
KR (1) KR100520737B1 (US06559137-20030506-C00128.png)
CN (2) CN101565412A (US06559137-20030506-C00128.png)
AP (1) AP1172A (US06559137-20030506-C00128.png)
AR (1) AR017965A1 (US06559137-20030506-C00128.png)
AT (1) ATE382042T1 (US06559137-20030506-C00128.png)
AU (1) AU755087B2 (US06559137-20030506-C00128.png)
BG (1) BG64869B1 (US06559137-20030506-C00128.png)
BR (1) BR9814480A (US06559137-20030506-C00128.png)
CA (1) CA2231700C (US06559137-20030506-C00128.png)
CO (1) CO4990992A1 (US06559137-20030506-C00128.png)
CZ (1) CZ301653B6 (US06559137-20030506-C00128.png)
DE (2) DE69838903T2 (US06559137-20030506-C00128.png)
DK (1) DK0933372T3 (US06559137-20030506-C00128.png)
EA (1) EA003509B1 (US06559137-20030506-C00128.png)
EE (1) EE04466B1 (US06559137-20030506-C00128.png)
ES (1) ES2299193T3 (US06559137-20030506-C00128.png)
FR (1) FR08C0015I2 (US06559137-20030506-C00128.png)
HK (1) HK1021737A1 (US06559137-20030506-C00128.png)
HU (2) HU229596B1 (US06559137-20030506-C00128.png)
ID (1) ID24962A (US06559137-20030506-C00128.png)
IL (2) IL136941A0 (US06559137-20030506-C00128.png)
IS (1) IS2817B (US06559137-20030506-C00128.png)
LU (1) LU91426I2 (US06559137-20030506-C00128.png)
ME (1) MEP82008A (US06559137-20030506-C00128.png)
MY (1) MY131525A (US06559137-20030506-C00128.png)
NL (1) NL300339I2 (US06559137-20030506-C00128.png)
NO (2) NO326265B1 (US06559137-20030506-C00128.png)
NZ (1) NZ505776A (US06559137-20030506-C00128.png)
OA (1) OA11468A (US06559137-20030506-C00128.png)
PE (1) PE20000048A1 (US06559137-20030506-C00128.png)
PL (1) PL202845B1 (US06559137-20030506-C00128.png)
PT (1) PT933372E (US06559137-20030506-C00128.png)
RS (1) RS52483B (US06559137-20030506-C00128.png)
SI (1) SI0933372T1 (US06559137-20030506-C00128.png)
SK (1) SK287123B6 (US06559137-20030506-C00128.png)
TR (1) TR200002615T2 (US06559137-20030506-C00128.png)
TW (1) TW486474B (US06559137-20030506-C00128.png)
UA (1) UA72733C2 (US06559137-20030506-C00128.png)
WO (1) WO1999033815A1 (US06559137-20030506-C00128.png)
ZA (1) ZA9811830B (US06559137-20030506-C00128.png)

Families Citing this family (158)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040122000A1 (en) * 1981-01-07 2004-06-24 Vertex Pharmaceuticals Incorporated. Inhibitors of aspartyl protease
UA59384C2 (uk) * 1996-12-20 2003-09-15 Пфайзер, Інк. Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
US6436989B1 (en) * 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
US6686366B1 (en) 1998-06-02 2004-02-03 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US6878716B1 (en) 1998-06-02 2005-04-12 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptor and uses thereof
WO1999062518A1 (en) 1998-06-02 1999-12-09 Osi Pharmaceuticals, Inc. PYRROLO[2,3d]PYRIMIDINE COMPOSITIONS AND THEIR USE
GB9815567D0 (en) * 1998-07-18 1998-09-16 Glaxo Group Ltd Antiviral compound
AU6329599A (en) * 1998-09-28 2000-04-17 Glaxo Group Limited Antiviral combinations comprising (s)-2-ethyl -7-fluoro -3-oxo-3, 4-dihydro -2h-quinoxaline -1-carboxylic acid isopropyl ester
GB9914821D0 (en) * 1999-06-24 1999-08-25 Glaxo Group Ltd Compounds
US7160890B2 (en) 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US6664252B2 (en) 1999-12-02 2003-12-16 Osi Pharmaceuticals, Inc. 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
US6680322B2 (en) 1999-12-02 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US6673802B2 (en) 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US7659404B2 (en) 2001-02-14 2010-02-09 Tibotec Pharmaceuticals Ltd. Broad spectrum 2-(substituted-amino)-benzothiazole sulfonamide HIV protease inhibitors
PL367084A1 (en) 2001-04-09 2005-02-21 Tibotec Pharmaceuticals Ltd. Broadspectrum 2-(substituted-amino)-benzoxazole sulfonamide hiv protease inhibitors
WO2002092595A1 (en) 2001-05-11 2002-11-21 Tibotec Pharmaceuticals Ltd. Broadspectrum 2-amino-benzoxazole sulfonamide hiv protease inhibitors
US7576084B2 (en) * 2001-10-12 2009-08-18 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
EP2050751A1 (en) 2001-11-30 2009-04-22 OSI Pharmaceuticals, Inc. Compounds specific to adenosine A1 and A3 receptors and uses thereof
TWI286476B (en) * 2001-12-12 2007-09-11 Tibotec Pharm Ltd Combination of cytochrome P450 dependent protease inhibitors
KR20040068317A (ko) 2001-12-20 2004-07-30 오에스아이 파마슈티컬스, 인코포레이티드 피리미딘 ａ₂ｂ 선택성 길항 화합물, 그의 합성 방법 및용도
CN1816551A (zh) 2001-12-20 2006-08-09 Osi药物公司 吡咯并嘧啶A2b选择性拮抗剂化合物,它们的合成及用途
BR0215260A (pt) 2001-12-21 2004-12-07 Tibotec Pharm Ltd Inibidores de hiv protease de sulfonamida contendo fenila substituìda heterocìclica de amplo espectro
US7157489B2 (en) * 2002-03-12 2007-01-02 The Board Of Trustees Of The University Of Illinois HIV protease inhibitors
MY142238A (en) 2002-03-12 2010-11-15 Tibotec Pharm Ltd Broadspectrum substituted benzimidazole sulfonamide hiv protease inhibitors
PL211979B1 (pl) 2002-04-26 2012-07-31 Gilead Sciences Pochodne fosfonianowe, ich zastosowanie w leczeniu zakażenia wirusem HIV i chorób wpływających na białe krwinki, oraz kompozycje farmaceutyczne zawierające te związki
DE60315984T2 (de) 2002-05-17 2008-05-29 Tibotec Pharmaceuticals Ltd. Substituierte benzisoxazolsulfonamide mit breitbändiger hiv-protease hemmender wirkung
CA2493940C (en) 2002-08-14 2011-11-22 Tibotec Pharmaceuticals Ltd. Broadspectrum substituted oxindole sulfonamide hiv protease inhibitors
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
CA2425031A1 (en) * 2003-04-01 2004-10-01 Smithkline Beecham Corporation Pharmaceutical compositions
WO2004096286A2 (en) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Antiviral phosphonate analogs
WO2005002626A2 (en) 2003-04-25 2005-01-13 Gilead Sciences, Inc. Therapeutic phosphonate compounds
MXPA05011296A (es) 2003-04-25 2006-01-24 Gilead Sciences Inc Conjugados de fosfonato inhibidores de la cinasa.
US7470724B2 (en) 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
US7452901B2 (en) 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
US7427636B2 (en) 2003-04-25 2008-09-23 Gilead Sciences, Inc. Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
US7300924B2 (en) 2003-04-25 2007-11-27 Gilead Sciences, Inc. Anti-infective phosphonate analogs
US7432261B2 (en) 2003-04-25 2008-10-07 Gilead Sciences, Inc. Anti-inflammatory phosphonate compounds
US7407965B2 (en) 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
WO2005009944A1 (en) * 2003-07-09 2005-02-03 Paratek Pharmaceuticals, Inc. Prodrugs of 9-aminomethyl tetracycline compounds
CN101863841A (zh) 2003-07-09 2010-10-20 帕拉特克药品公司 取代的四环素化合物
US20050119163A1 (en) 2003-09-18 2005-06-02 The Government Of The United States Of America, As Represented By The Secretary, SH2 domain binding inhibitors
US7427624B2 (en) 2003-10-24 2008-09-23 Gilead Sciences, Inc. Purine nucleoside phosphorylase inhibitory phosphonate compounds
US7432273B2 (en) 2003-10-24 2008-10-07 Gilead Sciences, Inc. Phosphonate analogs of antimetabolites
US20050131042A1 (en) * 2003-12-11 2005-06-16 Flentge Charles A. HIV protease inhibiting compounds
US8193227B2 (en) 2003-12-11 2012-06-05 Abbott Laboratories HIV protease inhibiting compounds
US7834043B2 (en) * 2003-12-11 2010-11-16 Abbott Laboratories HIV protease inhibiting compounds
CN102627609B (zh) * 2003-12-15 2016-05-04 默沙东公司 杂环天冬氨酰蛋白酶抑制剂
UA83881C2 (en) 2003-12-18 2008-08-26 Янссен Фармацевтика Н.В. Pyrido- and pyrimidopyrimidine derivatives as anti-proliferative agents
US7432272B2 (en) 2003-12-22 2008-10-07 Gilead Sciences, Inc. Antiviral analogs
CN101023090B (zh) 2004-07-06 2013-03-27 雅培制药有限公司 Hiv蛋白酶抑制剂的前药
WO2006110157A2 (en) 2004-07-27 2006-10-19 Gilead Sciences, Inc. Nucleoside phosphonate conjugates as anti hiv agents
US7388008B2 (en) * 2004-08-02 2008-06-17 Ambrilia Biopharma Inc. Lysine based compounds
CA2560071C (en) * 2004-08-02 2012-09-25 Brent Richard Stranix Lysine based compounds
WO2006024492A2 (en) 2004-08-30 2006-03-09 Interstitial Therapeutics Medical implant provided with inhibitors of atp synthesis
KR20070094754A (ko) 2004-12-01 2007-09-21 데브젠 엔브이 이온 채널, 특히 Ｋｖ 패밀리로부터의 이온 채널과상호작용하는 5-카복사미도 치환된 티아졸 유도체
NI200700147A (es) 2004-12-08 2019-05-10 Janssen Pharmaceutica Nv Derivados de quinazolina inhibidores de cinasas dirigidos a multip
US20080146445A1 (en) 2004-12-17 2008-06-19 Devgen Nv Nematicidal Compositions
PT1856135E (pt) * 2005-01-19 2010-02-26 Rigel Pharmaceuticals Inc Pró-fármacos de compostos 2,4-pirimidinodiamina e suas utilizações
EP1855672A4 (en) * 2005-03-11 2011-11-30 Glaxosmithkline Llc HIV PROTEASE INHIBITORS
AR053845A1 (es) 2005-04-15 2007-05-23 Tibotec Pharm Ltd 5-tiazolilmetil[(1s,2r)-3-[[(2-amino-6-benzoxazolil)sulfonil)](2-metilpropil)amino]-2-hidroxi-1-(fenilmetil)propil]carbamato como mejorador de farmacos metabolizados por el citocromo p450
CA2606025A1 (en) 2005-04-27 2006-11-02 Ambrilia Biopharma Inc. Method for improving pharmacokinetics of protease inhibitors and protease inhibitor precursors
EP1940856B1 (en) 2005-10-21 2014-10-08 Universiteit Antwerpen Novel urokinase inhibitors
AR058238A1 (es) 2005-11-28 2008-01-23 Tibotec Pharm Ltd Compuestos y derivados de aminofenilsulfonamida sustituida como inhibidores de proteasa del vih
TWI385173B (zh) 2005-11-28 2013-02-11 Tibotec Pharm Ltd 作為ｈｉｖ蛋白酶抑制劑之經取代的胺基苯基磺醯胺化合物
PL2289909T3 (pl) 2005-11-30 2015-04-30 Abbvie Inc Sposób przeszukiwania, proces oczyszczania niedyfundujących oligomerów Abeta, selektywne przeciwciała przeciw niedyfundującym oligomerom Abeta i sposób wytwarzania tych przeciwciał
US8497072B2 (en) 2005-11-30 2013-07-30 Abbott Laboratories Amyloid-beta globulomer antibodies
AU2006319716B2 (en) * 2005-11-30 2012-02-02 Taimed Biologics, Inc. Lysine-based prodrugs of aspartyl protease inhibitors and processes for their preparation
PL1968990T3 (pl) 2005-12-27 2015-06-30 Otsuka Pharma Co Ltd Rozpuszczalny w wodzie związek benzoazepinowy i jego kompozycja farmaceutyczna
DK2044084T3 (en) 2006-07-13 2016-05-09 Janssen Pharmaceutica Nv MTKI-quinazoline derivatives
EP2289564A3 (en) 2006-09-08 2012-11-14 Piramal Imaging SA Derivatives of aniline as precursors for F18-labeling
JP5401652B2 (ja) 2006-09-21 2014-01-29 タイメッド バイオロジクス インコーポレイテッド プロテアーゼ阻害剤
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008104386A2 (en) 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
AU2008226823B2 (en) 2007-03-12 2014-03-13 Nektar Therapeutics Oligomer-protease inhibitor conjugates
DK2185562T3 (en) 2007-07-27 2016-02-22 Janssen Pharmaceutica Nv PYRROLOPYRIMIDINES SUITABLE FOR TREATING PROLIFERATIVE DISEASES
EP2053033A1 (en) 2007-10-26 2009-04-29 Bayer Schering Pharma AG Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors
EP2100900A1 (en) 2008-03-07 2009-09-16 Universitätsspital Basel Bombesin analog peptide antagonist conjugates
ES2424982T3 (es) 2008-03-10 2013-10-10 Janssen Pharmaceutica, N.V. 4-Aril-2-anilino-pirimidinas como inhibidores de cinasas PLK
EP2262538B1 (en) * 2008-03-12 2014-12-10 Nektar Therapeutics Oligomer-amino acid conjugate
EP2116236A1 (en) 2008-04-21 2009-11-11 Université de Mons-Hainaut Bisbenzamidine derivatives for use as antioxidant
PL2307435T3 (pl) 2008-07-08 2012-11-30 Gilead Sciences Inc Sole związków inhibitorów HIV
NZ612380A (en) 2008-12-09 2015-01-30 Gilead Sciences Inc Modulators of toll-like receptors
EP2432788A1 (en) * 2009-05-20 2012-03-28 Ranbaxy Laboratories Limited Amorphous fosamprenavir calcium
WO2010144869A2 (en) 2009-06-12 2010-12-16 Nektar Therapeutics Protease inhibitors
CA2774483C (en) 2009-09-16 2014-11-18 Ranbaxy Laboratories Limited Process for the preparation of fosamprenavir calcium
WO2011061590A1 (en) 2009-11-17 2011-05-26 Hetero Research Foundation Novel carboxamide derivatives as hiv inhibitors
WO2011061295A1 (en) 2009-11-19 2011-05-26 Blue Medical Devices Bv Narrow profile composition-releasing expandable medical balloon catheter
US20110165202A1 (en) * 2010-01-07 2011-07-07 Pliva Hrvatska D.O.O. Solid state forms of fosamprenavir calcium salt and processes for preparation thereof
RS54123B1 (en) 2010-01-27 2015-12-31 Viiv Healthcare Company THERAPEUTIC COMBINATION CONTAINING DOLUTEGRAVIR, ABACAVIR AND LAMIVUDINE
US20110223131A1 (en) 2010-02-24 2011-09-15 Gilead Sciences, Inc. Antiviral compounds
US20110224443A1 (en) * 2010-03-15 2011-09-15 Venkata Naga Brahmeshwara Rao Mandava Preparation of fosamprenavir calcium
WO2011114212A1 (en) 2010-03-19 2011-09-22 Lupin Limited Ammonium, calcium and tris salts of fosamprenavir
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
WO2011141515A1 (en) 2010-05-14 2011-11-17 Bayer Pharma Aktiengesellschaft Diagnostic agents for amyloid beta imaging
US20130211108A1 (en) 2010-06-18 2013-08-15 Mylan Laboratories Ltd Novel process for the preparation of (3s)-tetrahydrofuran-3-yl (is, 2r)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-(phosphonooxy) propylcarbamate and its pharmaceutically acceptable salts
US8785648B1 (en) 2010-08-10 2014-07-22 The Regents Of The University Of California PKC-epsilon inhibitors
CA2808187A1 (en) 2010-08-14 2012-02-23 Abbvie Inc. Amyloid-beta binding proteins
US8877947B2 (en) * 2010-09-10 2014-11-04 Lupin Limited Process for preparation of substantially pure fosamprenavir calcium and its intermediates
GB201019043D0 (en) 2010-11-10 2010-12-22 Protea Biopharma N V Use of 2',5'-oligoadenylate derivative compounds
WO2012085625A1 (en) 2010-12-21 2012-06-28 Lupin Limited Process for the preparation of fosamprenavir calcium and intermediate used in its preparation
US8993786B2 (en) * 2011-02-10 2015-03-31 Mylan Laboratories Ltd. Crystalline fosamprenavir calcium and process for the preparation thereof
MX345095B (es) 2011-06-21 2017-01-17 Alnylam Pharmaceuticals Inc Composiciones de arni similares a angiopoyetina 3 (angptl3) y metodos para su uso.
EP4134433A1 (en) 2011-06-23 2023-02-15 Alnylam Pharmaceuticals, Inc. Serpina1 sirnas: compositions of matter and methods of treatment
WO2013009844A2 (en) * 2011-07-11 2013-01-17 Purdue Research Foundation C-3 substituted bicyclooctane based hiv protease inhibitors
WO2013011485A1 (en) 2011-07-20 2013-01-24 Ranbaxy Laboratories Limited Process for the preparation of sulfonamides useful as retroviral protease inhibitors
WO2013105118A1 (en) 2012-01-10 2013-07-18 Council Of Scientific & Industrial Research A process for synthesis of syn azido epoxide and its use as intermediate the synthesis of amprenavir & saquinavir
US9127274B2 (en) 2012-04-26 2015-09-08 Alnylam Pharmaceuticals, Inc. Serpinc1 iRNA compositions and methods of use thereof
EP2700396A3 (en) 2012-06-20 2015-04-29 Sylphar Nv Strip for the delivery of oral care compositions
WO2014059034A2 (en) 2012-10-09 2014-04-17 President And Fellows Of Harvard College Nad biosynthesis and precursors for the treatment and prevention of cancer and proliferation
AU2013340559B2 (en) 2012-10-29 2018-03-15 Cipla Limited Antiviral phosphonate analogues and process for preparation thereof
EP3336187A1 (en) 2012-12-05 2018-06-20 Alnylam Pharmaceuticals, Inc. Pcsk9 irna compositions and methods of use thereof
LT2970974T (lt) 2013-03-14 2017-12-11 Alnylam Pharmaceuticals, Inc. Komplemento komponento c5 irnr kompozicijos ir jų panaudojimas
EA038792B1 (ru) 2013-05-22 2021-10-20 Элнилэм Фармасьютикалз, Инк. КОМПОЗИЦИИ НА ОСНОВЕ RNAi Serpina1 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
TWI727917B (zh) 2013-05-22 2021-05-21 美商阿尼拉製藥公司 ＴＭＰＲＳＳ６ｉＲＮＡ 組成物及其使用方法
IL294470B1 (en) 2013-12-12 2024-08-01 Alnylam Pharmaceuticals Inc Complementary component iRNA compositions and methods for using them
CN106103718B (zh) 2014-02-11 2021-04-02 阿尔尼拉姆医药品有限公司 己酮糖激酶(KHK)iRNA组合物及其使用方法
WO2015175510A1 (en) 2014-05-12 2015-11-19 Alnylam Pharmaceuticals, Inc. Methods and compositions for treating a serpinc1-associated disorder
EP3146049B1 (en) 2014-05-22 2020-02-26 Alnylam Pharmaceuticals, Inc. Angiotensinogen (agt) irna compositions and methods of use thereof
EP3180003B1 (en) 2014-07-01 2022-01-12 The Regents of the University of California Pkc-epsilon inhibitors
WO2016001907A1 (en) 2014-07-02 2016-01-07 Prendergast Patrick T Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents.
CN113577081A (zh) 2014-07-11 2021-11-02 吉利德科学公司 用于治疗hiv的toll样受体调节剂
EP3191591A1 (en) 2014-09-12 2017-07-19 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting complement component c5 and methods of use thereof
WO2016061487A1 (en) 2014-10-17 2016-04-21 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof
WO2016069955A1 (en) 2014-10-29 2016-05-06 Wisconsin Alumni Research Foundation Boronic acid inhibitors of hiv protease
EP3212794B1 (en) 2014-10-30 2021-04-07 Genzyme Corporation Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof
WO2016081444A1 (en) 2014-11-17 2016-05-26 Alnylam Pharmaceuticals, Inc. Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof
WO2016083490A1 (en) 2014-11-27 2016-06-02 Remynd Nv Compounds for the treatment of amyloid-associated diseases
AU2016219263B2 (en) 2015-02-13 2022-12-01 Alnylam Pharmaceuticals, Inc. Patatin-like phospholipase domain containing 3 (PNPLA3) iRNA compositions and methods of use thereof
WO2016168286A1 (en) 2015-04-13 2016-10-20 Alnylam Pharmaceuticals, Inc. Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof
CN108025187A (zh) 2015-04-28 2018-05-11 新南创新私人有限公司 靶向nad+以治疗化学疗法和放射疗法引发的认知损害、神经病变和不活动
WO2016179342A2 (en) 2015-05-06 2016-11-10 Alnylam Pharmaceuticals, Inc. Factor xii (hageman factor) (f12), kallikrein b, plasma (fletcher factor) 1 (klkb1), and kininogen 1 (kng1) irna compositions and methods of use thereof
EP3310918B1 (en) 2015-06-18 2020-08-05 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
EP3350328A1 (en) 2015-09-14 2018-07-25 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting patatin-like phospholipase domain containing 3 (pnpla3) and methods of use thereof
AU2016322763A1 (en) 2015-09-15 2018-04-19 Gilead Sciences, Inc. Modulators of toll-like recptors for the treatment of HIV
JP6985283B2 (ja) 2015-12-07 2021-12-22 ジェンザイム・コーポレーション Ｓｅｒｐｉｎｃ１関連障害を処置するための方法および組成物
WO2017100542A1 (en) 2015-12-10 2017-06-15 Alnylam Pharmaceuticals, Inc. Sterol regulatory element binding protein (srebp) chaperone (scap) irna compositions and methods of use thereof
EP3469083A1 (en) 2016-06-10 2019-04-17 Alnylam Pharmaceuticals, Inc. COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
TWI788312B (zh) 2016-11-23 2023-01-01 美商阿尼拉製藥公司 絲胺酸蛋白酶抑制因子Ａ１ ｉＲＮＡ組成物及其使用方法
US20190350962A1 (en) 2016-12-16 2019-11-21 Alnylam Pharmaceuticals, Inc. METHODS FOR TREATING OR PREVENTING TTR-ASSOCIATED DISEASES USING TRANSTHYRETIN (TTR) iRNA COMPOSITIONS
PL3621963T3 (pl) 2017-05-11 2024-05-20 Remynd N.V. Związki do leczenia epilepsji, zaburzeń neurodegeneracyjnych i innych zaburzeń oun
CN111107850A (zh) 2017-07-21 2020-05-05 Viiv保健公司 用于治疗hib感染和aids的方案
PL3661937T3 (pl) 2017-08-01 2021-12-20 Gilead Sciences, Inc. Formy krystaliczne ((s)-((((2r,5r)-5-(6-amino-9h-puryn-9-ylo)-4-fluoro-2,5-dihydrofuran-2-ylo)oksy)metylo)(fenoksy)fosforylo)-l-alaninianu etylu (gs-9131) do leczenia zakażeń wirusowych
US11866701B2 (en) 2017-11-01 2024-01-09 Alnylam Pharmaceuticals, Inc. Complement component C3 iRNA compositions and methods of use thereof
EP3837366A1 (en) 2018-08-13 2021-06-23 Alnylam Pharmaceuticals, Inc. Hepatitis b virus (hbv) dsrna agent compositions and methods of use thereof
BR112021013956A2 (pt) 2019-01-16 2021-09-21 Genzyme Corporation Composições de irna de serpinc1 e métodos de uso das mesmas
WO2021154941A1 (en) 2020-01-31 2021-08-05 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
CN115175909A (zh) 2020-02-24 2022-10-11 鲁汶天主教大学 吡咯并吡啶和咪唑并吡啶抗病毒化合物
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
US12083099B2 (en) 2020-10-28 2024-09-10 Accencio LLC Methods of treating symptoms of coronavirus infection with viral protease inhibitors
WO2022136486A1 (en) 2020-12-22 2022-06-30 Luxembourg Institute Of Health (Lih) Conolidine analogues as selective ackr3 modulators for the treatment of cancer and cardiovascular diseases
WO2022184898A1 (en) 2021-03-04 2022-09-09 Universiteit Antwerpen Quinazolin-4-one and thieno[2,3-d]pyrimidin-4-one inhibitors of erbb4 (her4) for use in the treatment of cancer
US20240238460A1 (en) 2021-05-31 2024-07-18 Telix Pharmaceuticals (Innovations) Pty Ltd Improved prostate-specific membrane antigen targeting radiopharmaceuticals and uses thereof
WO2023021132A1 (en) 2021-08-18 2023-02-23 Katholieke Universiteit Leuven 6-substituted- and 6,7-disubstituted-7-deazapurine ribonucleoside analogues
EP4405357A1 (en) 2021-09-23 2024-07-31 Katholieke Universiteit Leuven KU Leuven Research & Development Ribonucleoside analogues against -sars-cov-2
WO2023241799A1 (en) 2022-06-15 2023-12-21 Université Libre de Bruxelles Flavanols for use in the treatment of retroviral infections
WO2024062043A1 (en) 2022-09-21 2024-03-28 Universiteit Antwerpen Substituted phenothiazines as ferroptosis inhibitors
WO2024175804A1 (en) 2023-02-24 2024-08-29 Katholieke Universiteit Leuven Nuclear transport modulators

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196438A (en) * 1989-12-11 1993-03-23 Hoffmann-La Roche Inc. Amino acid derivatives
WO1994005693A1 (de) * 1992-09-03 1994-03-17 Boehringer Ingelheim Kg Neue aminosäurederivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen
US5354866A (en) * 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3743722A (en) 1971-07-14 1973-07-03 Abbott Lab Anti-coagulant isolation
FR2459235A1 (fr) 1979-06-14 1981-01-09 Sanofi Sa Nouveaux derives de sulfonyl-aniline, leur procede de preparation et leur application therapeutique
JPS5946252A (ja) 1982-09-09 1984-03-15 Dainippon Ink & Chem Inc 含フツ素アミノカルボキシレ−トおよびその製法
JPS5948449A (ja) 1982-09-13 1984-03-19 Dainippon Ink & Chem Inc 直鎖状含フツ素アニオン化合物およびその製造方法
JPS6171830A (ja) 1984-09-17 1986-04-12 Dainippon Ink & Chem Inc 界面活性剤組成物
US4616088A (en) 1984-10-29 1986-10-07 E. R. Squibb & Sons, Inc. Amino acid ester and amide renin inhibitor
US4629724A (en) 1984-12-03 1986-12-16 E. R. Squibb & Sons, Inc. Amino acid ester and amide renin inhibitors
DE3635907A1 (de) 1986-10-22 1988-04-28 Merck Patent Gmbh Hydroxy-aminosaeurederivate
NL8800100A (nl) 1987-01-21 1988-08-16 Sandoz Ag Nieuwe peptidederivaten en werkwijzen voor het bereiden en toepassen van deze derivaten.
CA1340588C (en) 1988-06-13 1999-06-08 Balraj Krishan Handa Amino acid derivatives
IL91780A (en) 1988-10-04 1995-08-31 Abbott Lab History of the amine of the xenon-preventing xanine acid, the process for their preparation and the pharmaceutical preparations containing them
WO1990007330A1 (en) 1989-01-06 1990-07-12 The Regents Of The University Of California Selection method for specific useful pharmaceutical compounds
US5151438A (en) 1989-05-23 1992-09-29 Abbott Laboratories Retroviral protease inhibiting compounds
IE902295A1 (en) 1989-07-07 1991-01-16 Abbott Lab Amino acid analog cck antagonists
JPH07502970A (ja) 1990-06-01 1995-03-30 ザ・デュポン・メルク・ファーマシュウティカル・カンパニー １，４―ジアミノ―２，３―ジヒドロキシブタン類
TW225540B (US06559137-20030506-C00128.png) 1990-06-28 1994-06-21 Shionogi & Co
CA2096407C (en) 1990-11-19 2007-10-02 Kathryn Lea Reed Retroviral protease inhibitors
ATE196759T1 (de) 1990-11-19 2000-10-15 Monsanto Co Inhibitoren retroviraler proteasen
ES2059289T3 (es) 1990-11-19 1997-10-16 Monsanto Co Inhibidores de la proteasa retroviral.
AU9053191A (en) 1990-11-19 1992-06-11 Monsanto Company Retroviral protease inhibitors
IE20010533A1 (en) 1990-11-20 2003-03-05 Abbott Lab Intermediates for preparing retroviral protease inhibiting compounds
IL103613A (en) 1991-11-08 1999-05-09 Merck & Co Inc VIH protease inhibitors, and the process of preparing intermediates and pharmaceutical preparations containing them.
AU676479B2 (en) 1992-05-20 1997-03-13 G.D. Searle & Co. Method for making intermediates useful in synthesis of retroviral protease inhibitors
EP1447398A1 (en) 1992-05-21 2004-08-18 Monsanto Company Retroviral protease inhibitors
JP4091654B2 (ja) 1992-08-25 2008-05-28 ジー．ディー．サール、リミテッド、ライアビリティ、カンパニー レトロウイルスプロテアーゼ阻害剤として有用なスルホニルアルカノイルアミノヒドロキシエチルアミノスルホンアミド
PT810209E (pt) 1992-08-25 2002-09-30 Searle & Co Hidroxietilamino-sulfonamidas de alfa- e beta-aminoacidos uteis como inibidores de protease retroviral
WO1995006030A1 (en) 1993-08-24 1995-03-02 G.D. Searle & Co. Hydroxyethylamino sulphonamides useful as retroviral protease inhibitors
ES2103488T3 (es) 1992-08-25 1997-09-16 Searle & Co N-(alcanoilamino-2-hidroxipropil)sulfonamidas utiles como inhibidores de proteasas retrovirales.
US5783701A (en) * 1992-09-08 1998-07-21 Vertex Pharmaceuticals, Incorporated Sulfonamide inhibitors of aspartyl protease
IS2334B (is) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
US5723490A (en) * 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
TW372972B (en) 1992-10-23 1999-11-01 Novartis Ag Antiretroviral acyl compounds
ATE211462T1 (de) 1992-10-30 2002-01-15 Searle & Co N-substituierte hydroxyethylaminosulfamidsäure- derivate verwendbar als inhibitoren retroviraler proteasen
EP0885880A3 (en) 1992-10-30 1999-10-06 G.D. Searle & Co. Sulfonylalkanoylamino hydroxyethylamino sulfamic acids useful as retroviral protease inhibitors
US5484926A (en) 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
AU6135294A (en) 1993-02-12 1994-08-29 Merck & Co., Inc. Piperazine derivatives as hiv protease inhibitors
TW281669B (US06559137-20030506-C00128.png) 1993-02-17 1996-07-21 Chugai Pharmaceutical Co Ltd
IL110898A0 (en) 1993-09-10 1994-11-28 Narhex Australia Pty Ltd Polar-substituted hydrocarbons
IL111584A0 (en) 1993-11-18 1995-01-24 Merck & Co Inc Prodrugs of an inhibitor of hiv protease and pharmaceutical compositions containing them
US5527829A (en) 1994-05-23 1996-06-18 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
DE19506742A1 (de) 1995-02-27 1996-08-29 Bayer Ag Verwendung von Chinoxalinen in Kombination mit Protease-Inhibitoren als Arzneimittel zur Behandlung von AIDS und/oder HIV-Infektionen
US5691372A (en) 1995-04-19 1997-11-25 Vertex Pharmaceuticals Incorporated Oxygenated-Heterocycle containing sulfonamide inhibitors of aspartyl protease
US5750493A (en) 1995-08-30 1998-05-12 Raymond F. Schinazi Method to improve the biological and antiviral activity of protease inhibitors
US5646180A (en) 1995-12-05 1997-07-08 Vertex Pharmaceuticals Incorporated Treatment of the CNS effects of HIV
US6180634B1 (en) 1997-11-13 2001-01-30 Merck & Co., Inc. Combination therapy for the treatment of AIDS
US6436989B1 (en) * 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
CN1110492C (zh) * 1997-12-24 2003-06-04 沃泰克斯药物股份有限公司 天冬氨酰蛋白酶抑制剂的前药
TWI260322B (en) * 1999-02-12 2006-08-21 Vertex Pharma Inhibitors of aspartyl protease

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5354866A (en) * 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
US5196438A (en) * 1989-12-11 1993-03-23 Hoffmann-La Roche Inc. Amino acid derivatives
WO1994005693A1 (de) * 1992-09-03 1994-03-17 Boehringer Ingelheim Kg Neue aminosäurederivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen

Also Published As

Publication number Publication date
EE04466B1 (et) 2005-04-15
HUP0101831A2 (hu) 2002-04-29
EE200000385A (et) 2001-12-17
IL136941A (en) 2006-06-11
SK287123B6 (sk) 2009-12-07
EP0933372B1 (en) 2007-12-26
LU91426I2 (fr) 2008-06-02
US20100124543A1 (en) 2010-05-20
NL300339I1 (nl) 2008-06-02
TR200002615T2 (tr) 2001-01-22
ZA9811830B (en) 2000-06-23
FR08C0015I2 (fr) 2009-10-30
HUP0101831A3 (en) 2002-08-28
PL202845B1 (pl) 2009-07-31
CN1284071A (zh) 2001-02-14
IL136941A0 (en) 2001-06-14
US6436989B1 (en) 2002-08-20
YU39800A (sh) 2004-03-12
AU6546698A (en) 1999-07-19
US20050148548A1 (en) 2005-07-07
CO4990992A1 (es) 2000-12-26
EA200000703A1 (ru) 2000-12-25
PT933372E (pt) 2008-03-31
IS2817B (is) 2012-11-15
NO20003304D0 (no) 2000-06-23
LU91426I9 (US06559137-20030506-C00128.png) 2018-12-28
US20030207871A1 (en) 2003-11-06
AP2000001850A0 (en) 2000-06-30
CA2231700A1 (en) 1999-06-24
CZ301653B6 (cs) 2010-05-12
KR20010033600A (ko) 2001-04-25
RS52483B (en) 2013-02-28
OA11468A (en) 2004-05-05
MY131525A (en) 2007-08-30
NL300339I2 (nl) 2009-11-02
US6838474B2 (en) 2005-01-04
JP2005350478A (ja) 2005-12-22
NO326265B1 (no) 2008-10-27
TW486474B (en) 2002-05-11
EP1944300A3 (en) 2008-11-05
JP2009102400A (ja) 2009-05-14
DE69838903T2 (de) 2008-09-18
ES2299193T3 (es) 2008-05-16
JP4282639B2 (ja) 2009-06-24
AP1172A (en) 2003-06-30
PE20000048A1 (es) 2000-02-08
PL342113A1 (en) 2001-05-21
ATE382042T1 (de) 2008-01-15
CZ20002363A3 (cs) 2000-11-15
JP3736964B2 (ja) 2006-01-18
DE122008000021I1 (de) 2008-08-14
CN101565412A (zh) 2009-10-28
JPH11209337A (ja) 1999-08-03
AR017965A1 (es) 2001-10-24
KR100520737B1 (ko) 2005-10-12
NO2009008I2 (US06559137-20030506-C00128.png) 2010-09-27
DK0933372T3 (da) 2008-04-28
NO20003304L (no) 2000-08-21
ID24962A (id) 2000-08-31
BG64869B1 (bg) 2006-07-31
NZ505776A (en) 2003-06-30
IS5546A (is) 2000-06-22
HK1021737A1 (en) 2000-06-30
US7592368B2 (en) 2009-09-22
SI0933372T1 (sl) 2008-06-30
EP0933372A1 (en) 1999-08-04
ME00561B (me) 2011-10-10
MEP82008A (en) 2011-12-20
BG104631A (en) 2001-02-28
AU755087B2 (en) 2002-12-05
CA2231700C (en) 2005-08-09
HUS1400042I1 (hu) 2017-06-28
SK9662000A3 (en) 2001-02-12
HU229596B1 (en) 2014-02-28
DE69838903D1 (de) 2008-02-07
WO1999033815A1 (en) 1999-07-08
EA003509B1 (ru) 2003-06-26
US6559137B1 (en) 2003-05-06
BR9814480A (pt) 2001-09-25
UA72733C2 (en) 2005-04-15
NO2009008I1 (US06559137-20030506-C00128.png) 2009-05-04
FR08C0015I1 (US06559137-20030506-C00128.png) 2008-05-30
EP1944300A2 (en) 2008-07-16
DE122008000021I2 (de) 2010-02-04

Similar Documents

Publication Publication Date Title
CN100503589C (zh) 作为天冬氨酰蛋白酶抑制剂前药的磺胺衍生物
CN1110492C (zh) 天冬氨酰蛋白酶抑制剂的前药
WO1999033792A2 (en) Prodrugs os aspartyl protease inhibitors
CN1942436B (zh) 基于赖氨酸的化合物
MXPA00006315A (en) Sulphonamide derivatives as prodrugs of aspartyl protease inhibitors
MXPA00006316A (es) Profarmacos de inhibidores de aspartil proteasa
CN102093411A (zh) 基于赖氨酸的化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20090624